Literature DB >> 35996039

Significant liver fibrosis is a predictor of poor health-related quality of life in people living with HIV.

Maurice Michel1,2, Alisha Wahl1,2, Malena Anders1,2, Saleh A Alqahtani3,4, Wolfgang M Kremer2, Peter R Galle2, Christian Labenz1,2, Daniel Grimm2, Martin Sprinzl2, Jörn M Schattenberg5,6.   

Abstract

PURPOSE: Liver-related comorbidities can impair the health-related quality of life (HRQL) in people living with human immunodeficiency virus (HIV) (PLWH). However, the role of hepatic steatosis and significant fibrosis in PLWH remains incompletely characterized. Therefore, the aim of this study was to explore the association of hepatic steatosis and significant fibrosis on the HRQL using the medical outcomes study HIV health survey (MOS-HIV) in PLWH.
METHODS: A total of 222 PLWH were included in the final analysis of this cohort study. Metabolic comorbidities, socioeconomic factors, and HIV-related parameters were assessed. Hepatic steatosis and fibrosis were measured using vibration-controlled transient elastography (VCTE). The MOS-HIV survey, containing two summary scores (physical health summary (PHS) and mental health summary (MHS)) and ten domains, was used to assess the HRQL. Clinical predictors were identified using multivariable linear regression models.
RESULTS: The majority of this cohort was male, and the median age was 52 years, with a high prevalence of hepatic steatosis (n = 81, 36.5%). Significant fibrosis was present in 7.7% (n = 17). The mean PHS and MHS scores were 52.7 ± 9.5 and 51.4 ± 10.5, respectively. The lowest scores were in the general health perception (GHP) and energy/fatigue (EF) domains. A high BMI and waist circumference were associated with a poor PHS score. Lower education, unemployment, arterial hypertension, and significant fibrosis remained independent predictors of an impaired HRQL.
CONCLUSION: Metabolic comorbidities, significant fibrosis, and a lower socioeconomic status may negatively affect the HRQL in PLWH. Considering the negative impact of significant fibrosis on the outcome, counseling and preventive measures according to current guidelines are recommended in this subgroup of PLWH.
© 2022. The Author(s).

Entities:  

Keywords:  HIV; HRQL; MOS-HIV; Metabolic comorbidities; Significant fibrosis; VCTE

Year:  2022        PMID: 35996039     DOI: 10.1007/s11136-022-03232-w

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   3.440


  36 in total

1.  Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV : A Cohort Study.

Authors:  Bernard Surial; Catrina Mugglin; Alexandra Calmy; Matthias Cavassini; Huldrych F Günthard; Marcel Stöckle; Enos Bernasconi; Patrick Schmid; Philip E Tarr; Hansjakob Furrer; Bruno Ledergerber; Gilles Wandeler; Andri Rauch
Journal:  Ann Intern Med       Date:  2021-03-16       Impact factor: 25.391

2.  HIV-related stigma, racial discrimination, and gender discrimination: Pathways to physical and mental health-related quality of life among a national cohort of women living with HIV.

Authors:  Carmen H Logie; Ying Wang; Ashley Lacombe-Duncan; Anne C Wagner; Angela Kaida; Tracey Conway; Kath Webster; Alexandra de Pokomandy; Mona R Loutfy
Journal:  Prev Med       Date:  2017-12-22       Impact factor: 4.018

3.  Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events.

Authors:  Aslam H Anis; Bohdan Nosyk; Huiying Sun; Daphne P Guh; Nick Bansback; Xin Li; Paul G Barnett; Vilija Joyce; Kathleen M Swanson; Tassos C Kyriakides; Mark Holodniy; D William Cameron; Sheldon T Brown
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

4.  Adverse quality of life consequences of antiretroviral medications.

Authors:  L Y Park-Wyllie; C S Strike; T Antoniou; A M Bayoumi
Journal:  AIDS Care       Date:  2007-02

5.  HIV and metabolic syndrome: a comparison with the general population.

Authors:  Paolo Bonfanti; Cristina Giannattasio; Elena Ricci; Rita Facchetti; Elena Rosella; Marzia Franzetti; Laura Cordier; Luigi Pusterla; Michele Bombelli; Roberto Sega; Tiziana Quirino; Giuseppe Mancia
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-01       Impact factor: 3.731

6.  Trajectories of Health-Related Quality of Life and Perceived Social Support Among People Living With HIV Undergoing Antiretroviral Treatment: Does Gender Matter?

Authors:  Ewa Gruszczyńska; Marcin Rzeszutek
Journal:  Front Psychol       Date:  2019-07-23

7.  Stratifying the risk of NAFLD in patients with HIV under combination antiretroviral therapy (cART).

Authors:  Jenny Bischoff; Wenyi Gu; Carolynne Schwarze-Zander; Christoph Boesecke; Jan-Christian Wasmuth; Kathrin van Bremen; Leona Dold; Jürgen K Rockstroh; Jonel Trebicka
Journal:  EClinicalMedicine       Date:  2021-09-05

8.  Effect of hepatic steatosis and associated metabolic comorbidities on health-related quality of life in people living with HIV.

Authors:  Maurice Michel; Christian Labenz; Malena Anders; Alisha Wahl; Lisann Girolstein; Leonard Kaps; Wolfgang M Kremer; Yvonne Huber; Peter R Galle; Martin Sprinzl; Jörn M Schattenberg
Journal:  Hepatol Commun       Date:  2022-04-12

Review 9.  Consensus statement on the role of health systems in advancing the long-term well-being of people living with HIV.

Authors:  Jeffrey V Lazarus; Kelly Safreed-Harmon; Adeeba Kamarulzaman; Jane Anderson; Ricardo Baptista Leite; Georg Behrens; Linda-Gail Bekker; Sanjay Bhagani; Darren Brown; Graham Brown; Susan Buchbinder; Carlos Caceres; Pedro E Cahn; Patrizia Carrieri; Georgina Caswell; Graham S Cooke; Antonella d'Arminio Monforte; Nikos Dedes; Julia Del Amo; Richard Elliott; Wafaa M El-Sadr; María José Fuster-Ruiz de Apodaca; Giovanni Guaraldi; Tim Hallett; Richard Harding; Margaret Hellard; Shabbar Jaffar; Meaghan Kall; Marina Klein; Sharon R Lewin; Ken Mayer; Jose A Pérez-Molina; Doreen Moraa; Denise Naniche; Denis Nash; Teymur Noori; Anton Pozniak; Reena Rajasuriar; Peter Reiss; Nesrine Rizk; Jürgen Rockstroh; Diana Romero; Caroline Sabin; David Serwadda; Laura Waters
Journal:  Nat Commun       Date:  2021-07-16       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.